High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility

Molecular Oncology

Volumn 1, Issue 4, 2008, Pages 384-394

  Zieger, Karsten ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Microarray analysis; Molecular biology; Outcome assessment (health care); Urinary bladder neoplasms

Indexed keywords

CISPLATIN;

BIOINFORMATICS; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CARCINOMA; COLORECTAL CANCER; DIAGNOSTIC PROCEDURE; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; POPULATION; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VALIDATION PROCESS;

COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 40749132537     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2007.11.002     Document Type: Review

References (76)

1. Als A.B., Dyrskjøt L., von der Maase H., Koed K., Mansilla F., Toldbod H.E., et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res. 13 15 Pt 1 (2007 Aug 1) 4407-4414
2. Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol 22 12 (2004 Jun 15) 2284-2293
3. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 7035 (2005 Apr 14) 864-870
4. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 6 2 (2006 Feb) 107-116
5. Bernard-Pierrot I., Brams A., Dunois-Larde C., Caillault A., ez de Medina S.G., Cappellen D., et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27 4 (2006 Apr) 740-747
6. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 7074 (2006 Jan 19) 353-357
7. Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., Gil Diez de M.S., Van R.B., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol 158 6 (2001 Jun) 1955-1959
8. Blaveri E., Brewer J.L., Roydasgupta R., Fridlyand J., DeVries S., Koppie T., et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 11 19 Pt 1 (2005 Oct 1) 7012-7022
9. Blaveri E., Simko J.P., Korkola J.E., Brewer J.L., Baehner F., Mehta K., et al. Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res. 11 11 (2005 Jun 1) 4044-4055
10. Danesi D.T., Arcangeli G., Cruciani E., Altavista P., Mecozzi A., Saracino B., et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer 101 11 (2004 Dec 1) 2540-2548
11. Dehan E., Ben-Dor A., Liao W., Lipson D., Frimer H., Rienstein S., et al. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer 56 2 (2007 May) 175-184
12. Dressman H.K., Berchuck A., Chan G., Zhai J., Bild A., Sayer R., et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol 25 5 (2007 Feb 10) 517-525
13. Dupuy A., and Simon R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J. Natl. Cancer Inst 99 2 (2007 Jan 17) 147-157
14. Dyrskjøt L., Thykjaer T., Kruhoffer M., Jensen J.L., Marcussen N., Hamilton-Dutoit S., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33 1 (2003 Jan) 90-96
15. Dyrskjøt L., Kruhoffer M., Thykjaer T., Marcussen N., Jensen J.L., Moller K., et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64 11 (2004 Jun 1) 4040-4048
16. Dyrskjøt L., Zieger K., Kruhoffer M., Thykjaer T., Jensen J.L., Primdahl H., et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin. Cancer Res. 11 11 (2005 Jun 1) 4029-4036
17. Dyrskjøt L., Zieger K., Real F.X., Malats N., Carrato A., Hurst C., et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin. Cancer Res. 13 12 (2007 Jun 15) 3545-3551
18. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S., Nobel A.B., et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355 6 (2006 Aug 10) 560-569
19. Fox E.J., Leahy D.T., Geraghty R., Mulcahy H.E., Fennelly D., Hyland J.M., et al. Mutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer. J. Mol. Diagn 8 1 (2006 Feb) 68-75
20. Gildea J.J., Seraj M.J., Oxford G., Harding M.A., Hampton G.M., Moskaluk C.A., et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 62 22 (2002 Nov 15) 6418-6423
21. Gruvberger-Saal S.K., Cunliffe H.E., Carr K.M., and Hedenfalk I.A. Microarrays in breast cancer research and clinical practice-the future lies ahead. Endocr. Relat. Cancer 13 4 (2006 Dec) 1017-1031
22. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000 Jan 7) 57-70
23. Hoque M.O., Lee J., Begum S., Yamashita K., Engles J.M., Schoenberg M., et al. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res. 63 18 (2003 Sep 15) 5723-5726
24. Hoque M.O., Lee C.C., Cairns P., Schoenberg M., and Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res. 63 9 (2003 May 1) 2216-2222
25. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7 (2006) 96
26. Hughes S.J., Xi L., Raja S., Gooding W., Cole D.J., Gillanders W.E., et al. A rapid, fully automated, molecular-based assay accurately analyzes sentinel lymph nodes for the presence of metastatic breast cancer. Ann. Surg 243 3 (2006 Mar) 389-398
27. Jensen E.H., McLoughlin J.M., and Yeatman T.J. Microarrays in gastrointestinal cancer: is personalized prediction of response to chemotherapy at hand?. Curr. Opin. Oncol 18 4 (2006 Jul) 374-380
28. Kemming D., Vogt U., Tidow N., Schlotter C.M., Burger H., Helms M.W., et al. Whole genome expression analysis for biologic rational pathway modeling: application in cancer prognosis and therapy prediction. Mol. Diagn. Ther 10 5 (2006) 271-280
29. Killian A., Di F.F., Le P.F., Blanchard F., Lamy A., Raux G., et al. A simple method for the routine detection of somatic quantitative genetic alterations in colorectal cancer. Gastroenterology 132 2 (2007 Feb) 645-653
30. Kim J.H., Tuziak T., Hu L., Wang Z., Bondaruk J., Kim M., et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and non-papillary pathways. Lab. Invest 85 4 (2005 Apr) 532-549
31. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 27 3 (2006 Mar) 361-373
32. Koed K., Wiuf C., Christensen L.L., Wikman F.P., Zieger K., Moller K., et al. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res. 65 1 (2005 Jan 1) 34-45
33. Korn R., Rohrig S., Schulze-Kremer S., and Brinkmann U. Common denominator procedure: a novel approach to gene-expression data mining for identification of phenotype-specific genes. Bioinformatics 21 11 (2005 Jun 1) 2766-2772
34. Lai L.A., Paulson T.G., Li X., Sanchez C.A., Maley C., Odze R.D., et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 46 6 (2007 Jun) 532-542
35. Lebret T., Watson R.W., Molinie V., Poulain J.E., O'Neill A., Fitzpatrick J.M., et al. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Eur. Urol 51 1 (2007 Jan) 161-166
36. Lin Y.H., Friederichs J., Black M.A., Mages J., Rosenberg R., Guilford P.J., et al. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin. Cancer Res. 13 2 Pt 1 (2007 Jan 15) 498-507
37. Lindgren D., Liedberg F., Andersson A., Chebil G., Gudjonsson S., Borg A., et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 25 18 (2006 Apr 27) 2685-2696
38. Liu W., Guan M., Wu D., Zhang Y., Wu Z., Xu M., et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from non-cancer patients. Eur. Urol 47 4 (2005 Apr) 456-462
39. Michiels S., Koscielny S., and Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365 9458 (2005 Feb 5) 488-492
40. Mitra A.P., Datar R.H., and Cote R.J. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol 24 35 (2006 Dec 10) 5552-5564
41. Modlich O., Prisack H.B., Pitschke G., Ramp U., Ackermann R., Bojar H., et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin. Cancer Res. 10 10 (2004 May 15) 3410-3421
42. Munro N.P., Cairns D.A., Clarke P., Rogers M., Stanley A.J., Barrett J.H., et al. Urinary biomarker profiling in transitional cell carcinoma. Int. J. Cancer 119 11 (2006 Dec 1) 2642-2650
43. Muto S., Horie S., Takahashi S., Tomita K., and Kitamura T. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res. 60 15 (2000 Aug 1) 4021-4025
44. Naderi A., Teschendorff A.E., Barbosa-Morais N.L., Pinder S.E., Green A.R., Powe D.G., et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26 10 (2007 Mar 1) 1507-1516
45. Nakao K., Mehta K.R., Fridlyand J., Moore D.H., Jain A.N., Lafuente A., et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 25 8 (2004 Aug) 1345-1357
46. Nevins J.R., Huang E.S., Dressman H., Pittman J., Huang A.T., and West M. Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum. Mol. Genet No 2 (2003 Oct 15;12 Spec) R153-R157
47. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10 16 (2004 Aug 15) 5367-5374
48. Ntzani E.E., and Ioannidis J.P. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362 9394 (2003 Nov 1) 1439-1444
49. Patard J.J., Rodriguez A., and Lobel B. The current status of intravesical therapy for superficial bladder cancer. Curr. Opin. Urol 13 5 (2003 Sep) 357-362
50. Paterson A.L., Pole J.C., Blood K.A., Garcia M.J., Cooke S.L., Teschendorff A.E., et al. Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event. Genes Chromosomes Cancer 46 5 (2007 May) 427-439
51. Perreard L., Fan C., Quackenbush J.F., Mullins M., Gauthier N.P., Nelson E., et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 8 2 (2006) R23
52. Pospisil P., Iyer L.K., Adelstein S.J., and Kassis A.I. A combined approach to data mining of textual and structured data to identify cancer-related targets. BMC Bioinformatics 7 (2006) 354
53. Purdie K.J., Lambert S.R., Teh M.T., Chaplin T., Molloy G., Raghavan M., et al. Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer 46 7 (2007 Jul) 661-669
54. Reddy G.K., and Balk S.P. Clinical utility of microarray-derived genetic signatures in predicting outcomes in prostate cancer. Clin. Genitourin Cancer 5 3 (2006 Dec) 187-189
55. Rennstam K., Ahlstedt-Soini M., Baldetorp B., Bendahl P.O., Borg A., Karhu R., et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res. 63 24 (2003 Dec 15) 8861-8868
56. Sanchez-Carbayo M., Socci N.D., Lozano J.J., Li W., Charytonowicz E., Belbin T.J., et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am. J. Pathol 163 2 (2003 Aug) 505-516
57. Sanchez-Carbayo M., Socci N.D., Lozano J., Saint F., and Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol 24 5 (2006 Feb 10) 778-789
58. Schrier B.P., Hollander M.P., van Rhijn B.W., Kiemeney L.A., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur. Urol 45 3 (2004 Mar) 292-296
59. Schultz I.J., Wester K., Straatman H., Kiemeney L.A., Babjuk M., Mares J., et al. Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int. J. Cancer 119 8 (2006 Oct 15) 1915-1919
60. Sorensen F.J., Andersen C.L., and Wiuf C. SNPTools: a software tool for visualization and analysis of microarray data. Bioinformatics (2007 Mar 28)
61. Sorlie T., Wang Y., Xiao C., Johnsen H., Naume B., Samaha R.R., et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7 (2006) 127
62. Sotiriou C., and Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat. Rev. Cancer 7 7 (2007 Jul) 545-553
63. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst 98 4 (2006 Feb 15) 262-272
64. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 43 (2005 Oct 25) 15545-15550
65. Sun Z., and Yang P. Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise. Cancer Epidemiol. Biomarkers Prev 15 11 (2006 Nov) 2063-2068
66. Takata R., Katagiri T., Kanehira M., Tsunoda T., Shuin T., Miki T., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 11 7 (2005 Apr 1) 2625-2636
67. Takata R., Katagiri T., Kanehira M., Shuin T., Miki T., Namiki M., et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 98 1 (2007 Jan) 113-117
68. Theodorescu D., Sapinoso L.M., Conaway M.R., Oxford G., Hampton G.M., and Frierson Jr. H.F. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin. Cancer Res. 10 11 (2004 Jun 1) 3800-3806
69. Trautmann K., Terdiman J.P., French A.J., Roydasgupta R., Sein N., Kakar S., et al. Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin. Cancer Res. 12 21 (2006 Nov 1) 6379-6385
70. Vauhkonen H., Vauhkonen M., Sajantila A., Sipponen P., and Knuutila S. Characterizing genetically stable and unstable gastric cancers by microsatellites and array comparative genomic hybridization. Cancer Genet. Cytogenet 170 2 (2006 Oct 15) 133-139
71. Vlahou A., Schellhammer P.F., Mendrinos S., Patel K., Kondylis F.I., Gong L., et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol 158 4 (2001 Apr) 1491-1502
72. Warnat P., Eils R., and Brors B. Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics 6 (2005) 265
73. Wild P.J., Herr A., Wissmann C., Stoehr R., Rosenthal A., Zaak D., et al. Gene expression profiling of progressive papillary non-invasive carcinomas of the urinary bladder. Clin. Cancer Res. 11 12 (2005 Jun 15) 4415-4429
74. Wolf H., Iversen H.G., Rosenkilde P., and Schroder T. Transurethral surgery in the treatment of invasive bladder cancer (T1 and T2). Scand. J. Urol. Nephrol. Suppl. 104 (1987) 127-132
75. Zhao H., Ljungberg B., Grankvist K., Rasmuson T., Tibshirani R., and Brooks J.D. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 3 1 (2006 Jan) e13
76. Zieger K., Dyrskjøt L., Wiuf C., Jensen J.L., Andersen C.L., Jensen K.M., et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin. Cancer Res. 11 21 (2005 Nov 1) 7709-7719